AstraZeneca SVP Mani Sharma Acquires Shares via Dividend Reinvestment & Incentive Plan

Executive Summary

On September 11, 2026, AstraZeneca PLC (NASDAQ/LSE: AZN) filed a Form 4 disclosing two minor routine share acquisitions by Mani Sharma, SVP, Group Controller and Head of Global Finance Services. The transactions totaled 21.233 ordinary shares valued at approximately $3,411.41.

Transaction Breakdown

1. Dividend Reinvestment (August 8, 2026):

   • Code: P (Open market or private purchase)
   • Shares Acquired: 20.233 Ordinary Shares
   • Price per Share: $160.57 (£118.96 converted at 1.3498 USD/GBP)
   • Context: Represents the automatic reinvestment of dividends accrued under the Issuer's Restricted Share Plan, subject to a three-year holding period.

2. Share Incentive Plan (September 8, 2026):

   • Code: A (Grant/Award/Acquisition under plan)
   • Shares Acquired: 1.000 Ordinary Share
   • Price per Share: $162.60 (£120.26 converted at 1.3521 USD/GBP)
   • Context: Standard acquisition pursuant to the Issuer's Share Incentive Plan.

Ownership Post-Transaction

Following these transactions, Mani Sharma directly holds 19,288.6989 Ordinary Shares of AstraZeneca PLC.

Significance Assessment

Trading Significance: Low. These transactions represent routine plan-based acquisitions and dividend reinvestments rather than discretionary open-market insider buying.